Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability

BackgroundThe cerebral subcortical deep gray matter nuclei (DGM) are a common, early, and clinically-relevant site of atrophy in multiple sclerosis (MS). Robust and reliable DGM segmentation could prove useful to evaluate putative neuroprotective MS therapies. The objective of the study was to compare the sensitivity and reliability of DGM volumes obtained from 1.5T vs. 3T MRI.MethodsFourteen patients with MS [age (mean, range) 50.2 (32.0–60.8) years, disease duration 18.4 (8.2–35.5) years, Expanded Disability Status Scale score 3.1 (0–6), median 3.0] and 15 normal controls (NC) underwent brain 3D T1-weighted paired scan-rescans at 1.5T and 3T. DGM (caudate, thalamus, globus pallidus, and putamen) segmentation was obtained by the fully automated FSL-FIRST pipeline. Both raw and normalized volumes were derived.ResultsDGM volumes were generally higher at 3T vs. 1.5T in both groups. For raw volumes, 3T showed slightly better sensitivity (thalamus: p = 0.02; caudate: p = 0.10; putamen: p = 0.02; globus pallidus: p = 0.0004; total DGM: p = 0.01) than 1.5T (thalamus: p = 0.05; caudate: p = 0.09; putamen: p = 0.03; globus pallidus: p = 0.0006; total DGM: p = 0.02) for detecting DGM atrophy in MS vs. NC. For normalized volumes, 3T but not 1.5T detected atrophy in the globus pallidus in the MS group. Across all subjects, scan-rescan reliability was generally very high for both platforms, showing slightly higher reliability for some DGM volumes at 3T. Raw volumes showed higher reliability than normalized volumes. Raw DGM volume showed higher reliability than the individual structures.ConclusionsThese results suggest somewhat higher sensitivity and reliability of DGM volumes obtained from 3T vs. 1.5T MRI. Further studies should assess the role of this 3T pipeline in tracking potential MS neurotherapeutic effects.

[1]  C. Guttmann,et al.  Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  Massimo Filippi,et al.  A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes , 2008, NeuroImage.

[3]  B. J. Winer Statistical Principles in Experimental Design , 1992 .

[4]  R. Bakshi,et al.  Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[5]  M. Dwyer,et al.  Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.

[6]  R. Bakshi,et al.  Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review , 2017, JAMA neurology.

[7]  E. Waubant,et al.  Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis , 2016, Journal of the Neurological Sciences.

[8]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[9]  Rohit Bakshi,et al.  Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[10]  Hon-Man Liu,et al.  Reproducibility of Brain Morphometry from Short-Term Repeat Clinical MRI Examinations: A Retrospective Study , 2016, PloS one.

[11]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[12]  M. Schlamann,et al.  First Clinical Study on Ultra-High-Field MR Imaging in Patients with Multiple Sclerosis: Comparison of 1.5T and 7T , 2009, American Journal of Neuroradiology.

[13]  Hans Lassmann,et al.  The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.

[14]  C. Crainiceanu,et al.  Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling☆ , 2013, NeuroImage: Clinical.

[15]  Robert L. Mason,et al.  Statistical Principles in Experimental Design , 2003 .

[16]  G. Tsivgoulis,et al.  The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis , 2015, PloS one.

[17]  Seth E. Bouvier,et al.  Comparison of Multiple Sclerosis Lesions at 1.5 and 3.0 Tesla , 2003, Investigative radiology.

[18]  Rohit Bakshi,et al.  Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis , 2017, The International journal of neuroscience.

[19]  P. Kalavathi,et al.  Methods on Skull Stripping of MRI Head Scan Images—a Review , 2016, Journal of Digital Imaging.

[20]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[21]  F. Barkhof,et al.  Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method , 2016, PloS one.

[22]  Craig K. Jones,et al.  Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology , 2015, Multiple sclerosis.

[23]  J S Wolinsky,et al.  EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis , 2006, European journal of neurology.

[24]  Anders M. Dale,et al.  MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths , 2009, NeuroImage.

[25]  C. Poser,et al.  Diagnostic criteria for multiple sclerosis , 2001, Clinical Neurology and Neurosurgery.

[26]  Rohit Bakshi,et al.  Role of MRI in multiple sclerosis I: inflammation and lesions. , 2004, Frontiers in bioscience : a journal and virtual library.

[27]  Xiao-Li Meng,et al.  Comparing correlated correlation coefficients , 1992 .

[28]  R. Bakshi,et al.  Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. , 2010, Annals of neurology.

[29]  R. Bakshi,et al.  Corpus Callosum Atrophy Correlates with Gray Matter Atrophy in Patients with Multiple Sclerosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[30]  Massimo Filippi,et al.  Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study , 2006, The Lancet Neurology.

[31]  Rohit Bakshi,et al.  Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models , 2015, NeuroImage: Clinical.

[32]  C. Jack,et al.  Comparing 3T and 1.5T MRI for Mapping Hippocampal Atrophy in the Alzheimer's Disease Neuroimaging Initiative , 2015, American Journal of Neuroradiology.

[33]  Rohit Bakshi,et al.  Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[34]  J A Frank,et al.  MRI T2 lesion burden in multiple sclerosis , 2006, Neurology.

[35]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[36]  Sheena L. Dupuy,et al.  The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis , 2016, Neurology and Therapy.

[37]  D. Reich,et al.  Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis , 2017, American Journal of Neuroradiology.

[38]  C R G Guttmann,et al.  Thalamic atrophy and cognition in multiple sclerosis , 2007, Neurology.

[39]  D. Ramasamy,et al.  Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[40]  D. Ontaneda,et al.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives , 2015, The Lancet Neurology.